Pancreatic Neuroendocrine Tumor Clinical Trials

12 recruiting

Pancreatic Neuroendocrine Tumor Trials at a Glance

34 actively recruiting trials for pancreatic neuroendocrine tumor are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in St Louis, Detroit, and Nashville. Lead sponsors running pancreatic neuroendocrine tumor studies include IRCCS San Raffaele, Jiangsu HengRui Medicine Co., Ltd., and National Cancer Institute (NCI).

Browse pancreatic neuroendocrine tumor trials by phase

Treatments under study

About Pancreatic Neuroendocrine Tumor Clinical Trials

Looking for clinical trials for Pancreatic Neuroendocrine Tumor? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Neuroendocrine Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Neuroendocrine Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2Phase 3

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Not Applicable

Nutrition Intervention for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neuroendocrine Tumors (pNET)
Children's Hospital of Philadelphia18 enrolled2 locationsNCT07554560
Recruiting
Phase 1

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Pancreatic NeoplasmMetastatic Pancreatic Neuroendocrine TumorStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI)24 enrolled10 locationsNCT05687123
Recruiting
Phase 2

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)740 enrolled1 locationNCT04074135
Recruiting
Phase 2Phase 3

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled80 locationsNCT06943755
Recruiting
Phase 3

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.220 enrolled1 locationNCT05884255
Recruiting
Not Applicable

Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

Endoscopic Ultrasound-Guided Radiofrequency AblationPancreatic Neuroendocrine Tumors (pNET)Pancreatic Cystic Neoplasms
Institute for Clinical and Experimental Medicine50 enrolled1 locationNCT07536087
Recruiting
Not Applicable

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Pancreatic Neuroendocrine TumorMedullary Thyroid CancerAdrenal Cortical Carcinoma+1 more
Shanghai Jiao Tong University School of Medicine21 enrolled1 locationNCT06141369
Recruiting

Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

Pancreatic Neuroendocrine TumorSolid Pancreatic Neoplasms
Fudan University1,000 enrolled2 locationsNCT05847855
Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System50 enrolled2 locationsNCT04090034
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting

AI-Powered Precision Decision-Making for Pancreatic Diseases

Pancreatic CancerPancreatic Neuroendocrine TumorChronic Pancreatitis+4 more
Changhai Hospital2,000 enrolled1 locationNCT07439757
Recruiting
Not Applicable

Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

Pancreatic Neuroendocrine Tumor
Uppsala University200 enrolled4 locationsNCT07273409
Recruiting
Not Applicable

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy

Pancreatic Ductal AdenocarcinomaPancreatic Neuroendocrine TumorAmpullary Carcinoma+2 more
Minia University90 enrolled1 locationNCT07328607
Recruiting
Phase 1

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor
University of Chicago25 enrolled1 locationNCT06663072
Recruiting
Phase 4

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Malignant Neoplasm in the LiverDigestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2+3 more
Vanderbilt-Ingram Cancer Center6 enrolled1 locationNCT06016855